Trial Profile
A Phase I/Randomized Phase II Study of Cediranib (NSC 732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2018 Primary endpoint (Progression-free survival (Phase II)) has been met, according to the results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 10 May 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.